| __timestamp | CRISPR Therapeutics AG | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 72471000 |
| Thursday, January 1, 2015 | 13403000 | 89204000 |
| Friday, January 1, 2016 | 31056000 | 106010000 |
| Sunday, January 1, 2017 | 35845000 | 137905000 |
| Monday, January 1, 2018 | 48294000 | 159888000 |
| Tuesday, January 1, 2019 | 63488000 | 158425000 |
| Wednesday, January 1, 2020 | 88208000 | 200677000 |
| Friday, January 1, 2021 | 102802000 | 304759000 |
| Saturday, January 1, 2022 | 102464000 | 377221000 |
| Sunday, January 1, 2023 | 76162000 | 336361000 |
| Monday, January 1, 2024 | 72977000 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology and pharmaceuticals, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, CRISPR Therapeutics AG and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses.
CRISPR Therapeutics AG, a pioneer in gene-editing technology, saw its SG&A expenses grow by approximately 1,400% from 2014 to 2021, peaking in 2021. However, 2023 marked a decline of about 26% from its 2021 high. In contrast, Supernus Pharmaceuticals, Inc., known for its focus on central nervous system disorders, experienced a steady increase, with expenses rising by over 360% during the same period, reaching their zenith in 2022.
These trends reflect strategic shifts and market dynamics, offering insights into each company's operational focus and market positioning.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Biogen Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
Alpine Immune Sciences, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Wave Life Sciences Ltd. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Galapagos NV
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights